{
  "url": "https://openlegislation.uk/medicines-applications-for-grant-of-product-licencesproducts-for-human-use-regulations-1993/note",
  "json_url": "https://openlegislation.uk/medicines-applications-for-grant-of-product-licencesproducts-for-human-use-regulations-1993/note.json",
  "legislation": "uksi/1993/2538",
  "legislation_title": "The Medicines (Applications for Grant of Product Licences—Products for Human Use) Regulations 1993",
  "legislation_url": "https://openlegislation.uk/medicines-applications-for-grant-of-product-licencesproducts-for-human-use-regulations-1993",
  "path": "note",
  "kind": "note",
  "number": null,
  "heading": "Explanatory note",
  "text": "(This note is not part of the Regulations)\nThese Regulations prescribe the information, documents, samples and other material to be provided in or with an application, made after the coming into force of the Regulations, for a product licence under Part II of the Medicines Act 1968 (“the Act”) in relation to medicinal products for human use. They replace, in relation to such applications, the requirements of the Medicines (Applications for Product Licences and Clinical Trial and Animal Test Certificates) Regulations 1971 (S.I. 1971/973) which are amended in consequence.\nThe Regulations set out the requirements laid down in—\nArticle 4 (particulars and documents to accompany an application) of Council Directive 65/65/EEC (OJ No. 22, 9.2.65, p.369/65 (OJ/SE 1965–66, p.20)) as amended and supplemented by Article 35 of Directive 75/319/EEC (OJ No. L147, 9.6.75, p.13), Articles 1.1(a) and (c) of Council Directive 83/570/EEC (OJ No. L332, 28.11.83, p.1), Article 1.1 of Council Directive 87/21/EEC (OJ No. L15, 17.1.87, p.36) and Article 3 of Council Directive 89/343/EEC (OJ No. L142, 25.5.89, p.16), and\nArticle 4a (information to be contained in the summary of product characteristics) of Directive 65/65/EEC as inserted by Article 1.2 of Council Directive 83/570/EEC and as amended and supplemented by Article 1.4 of Council Directive 89/341/EEC (OJ No. L142, 25.5.89, p.11), Article 3 of Council Directive 89/342/EEC (OJ No. L142, 25.5.89, p.14) and Article 4 of Directive 89/343/EEC,\n(regulation 4(1) and Schedule 1) subject to minor adaptations to take account of the existing framework of the Act and relevant subordinate legislation made under it, and to modified ordering of the summary of product characteristics.\nThe Regulations also incorporate from other relevant Directives various additional specific items and other provisions of major substance required by those Directives, most notably the provisions concerning experts' reports laid down in Articles 1 and 2 of Council Directive 75/319/EEC (see the definition of “expert” in regulation 1(2), and paragraphs 12 and 13 of Schedule 1). They incorporate by reference (see regulation 4(1) and the definition of “the Directives” in regulation 1(2)) the more detailed requirements of those Directives as to the preparation and presentation of the material (in particular those set out in the new Annex to Council Directive 75/318/EEC (OJ No. L147, 9.6.75, p.1) as substituted by Commission Directive 91/507/EEC (OJ No. L270, 26.9.91, p.32).\nSchedule 2 to the Regulations sets out special circumstances in which the results of pharmacological and toxicological tests or clinical trials need not be provided. Paragraphs 1 to 4 reflect the provisions of Article 4.8(a) of Directive 65/65/EEC, dealing with circumstances where the product for which a licence is sought is essentially similar to an existing licensed product, or where the relevant information is available from published scientific literature. Paragraph 5 deals with the special exceptions set out in Part 4, paragraph G of the new Annex to Council Directive 75/318/EEC concerning circumstances where comprehensive evidence cannot be provided because of the rarity of the relevant medical conditions, deficiencies in the state of scientific knowledge or ethical objections to carrying out tests.\nSchedule 3 sets out the “drug master file” provisions laid down in Part 2, paragraph C.1 of the new Annex to Directive 75/318/EEC, under which the details of active ingredients manufactured by someone other than the applicant may, in certain circumstances, be supplied by the manufacturer instead of by the applicant.\nThe Regulations also provide that the same requirements as to the material to be provided in or with applications apply in relation to products which are not covered by the Directives as apply in relation to those which are (regulation 4(2)).\nThe Medicines (Standard Provisions for Licences and Certificates) Amendment (No. 2) Regulations 1993 (S.I. 1993/2539) amongst other things make related provision to deal with, in particular, the provision to the licensing authority of new information and, in special circumstances (see paragraph 22 of Schedule 1 to these Regulations), the carrying out of a specified programme of studies, after the grant of a licence.",
  "extent": null,
  "status": null,
  "version": "current",
  "annotations": [],
  "outstanding_effects": [],
  "provenance": {
    "source": "legislation.gov.uk",
    "source_url": "https://www.legislation.gov.uk/uksi/1993/2538/note",
    "retrieved_at": "2026-10-29T13:49:32.233655+00:00"
  },
  "licence": "Open Government Licence v3.0",
  "licence_url": "https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/",
  "attribution": "Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives."
}